Barron's : Elon Musk’s $1.8 Trillion SpaceX IPO Is Too Big to Succeed

Elon Musk’s $1.8 Trillion SpaceX IPO Is Too Big to Succeed
While the company is spectacular, the stock is too expensive to justify the risks.

SpaceX targets a $75 billion IPO raise at $135 per share, potentially valuing the company at $1.8 trillion, though fair value may be closer to $1 trillion.
Starlink generated $7.2 billion EBITDA in 2025 with over 60% margins, while the xAI acquisition led to a $6.4 billion operating loss.
SpaceX aims for 70% gross and 45% net income margins, 10 percentage points above Alphabet.

The SpaceX initial public offering is one of a kind; the investment opportunity is not. With a roughly $1.8 trillion valuation, the stock may be too big to reach escape velocity.

SpaceX’s IPO is arguably the biggest capital-markets event ever. There is the sheer size—a record $75 billion raise is targeted, excluding overallotment options for bankers to buy an additional 83.3 million shares; the offering price isn’t a range, but a specific price of $135; and the ultimate value of the company could hit $1.8 trillion. SpaceX’s singularity will continue when it starts trading, with the company added to the Nasdaq 100 just 15 trading days after the offering, requiring passive buying of 10% to 15% of the shares outstanding, and a massive amount of retail participation in the IPO.

Yet despite the superlatives, SpaceX is just a company. Yes, it’s the world’s dominant space company, having leveraged lower costs from reusable rockets to build Starlink, a space-based broadband product with more than 10 million customers. But it’s also the world’s most valuable money-losing company, competing with the likes of OpenAI and Anthropic, and one of the most expensive, trading at 40 times estimated 2026 sales and 175 times earnings before interest, taxes, depreciation, and amortization, or Ebitda. For investors considering buying the IPO, it is worth waiting for the stock to trade closer to fair value, which likely sits nearer $1 trillion than $2 trillion.

SpaceX, despite its name, isn’t just a space company—far from it. Its launch segment is a solid business that was profitable before suffering an operating loss of $657 million in 2025. That deficit was the result of SpaceX’s spending on its huge, fully reusable Starship rocket, which set the company back some $15 billion over time. But Starship is also the key to SpaceX’s future: It is expected to lower costs to reach orbit by 90% compared with its Falcon 9 rocket, which had already slashed costs to reach space by 95% compared with the Space Shuttle.

SpaceX’s most profitable unit is its Starlink space-based broadband business, built on satellites launched by the company. It generated earnings before interest, taxes, depreciation, and amortization, or Ebitda, of $7.2 billion in 2025, up about 90% year over year. Ebitda profit margins are north of 60%, better than the 38% generated by telecom companies, including AT&T, T-Mobile US, and Verizon Communications. Revenue and Ebitda should grow rapidly in the coming years as SpaceX targets global broadband and mobile markets worth $1.6 trillion.

Not everything is pretty. Consider SpaceX’s artificial-intelligence business, grafted onto the company when it purchased xAI for $250 billion in February. It generated an operating loss of $6.4 billion in 2025 and a first-quarter loss of $2.5 billion. xAI, which has been dissolved as a corporate entity, spent $12.7 billion in 2025, while AI spending hit $7.7 billion in the first quarter. Losses should be mitigated by selling computing power to Anthropic and Google for $1.25 billion and $920 million a month, respectively. Others seeking computing power could turn to SpaceX as well.

Placing a valuation on all of this isn’t easy. Morningstar recently valued SpaceX for about $780 billion, which includes just $170 billion for AI.(OpenAI and Anthropic, by comparison, will seek trillion-dollar valuations in coming IPOs.) New York University professor and valuation maven Aswath Damodaran values SpaceX at about $1.3 trillion, or $99 a share. To get there, he assumes $420 billion in 2036 revenue, including $40 billion from space, $120 billion from Starlink—a number on par with AT&T today—$160 billion from AI and $100 billion from “other” opportunities that low-cost launch enables but aren’t evident yet. (SpaceX will have a defense business.) Margins in the launch and Starlink businesses are similar to what SpaceX is producing. AI and “other” operating margins look like OK software margins today. Bottom line, that yields $160 billion in 2036 operating profit. That is just shy of what Alphabet will generate in 2026.

The Alphabet comparison is a good one. What began as a search company has become so much more. Alphabet is expected to generate about $231 billion of Ebitda in 2026 from search, YouTube, Waymo, Android, cloud services, and Gemini. For SpaceX to grow into its valuation, it will need to develop profitable AI applications or a cloud-based computing franchise that generates hundreds of billions in profits. In the long run, SpaceX is targeting gross profit margins of 70% and net income margins of 45%, about 10 percentage points better than Alphabet on both metrics.

Expecting Alphabet-like returns from the SpaceX IPO is asking too much. Google was a less mature company—it had been in business for six years to SpaceX’s 24—when it went public in 2004. Google’s IPO price was $85 a share, or $2.125 after accounting for stock splits, and left the company with a market capitalization of about $23 billion. Alphabet stock has gained 17,000% since then. To generate that kind of return will require SpaceX to earn a market valuation of $300 trillion.

That is a lot, even for a company run by Elon Musk. The Tesla CEO and SpaceX founder is an innovator whose most important gift might be getting people to believe in the seemingly impossible—like $20,000 robots doing all humanity’s hard labor. His fans are devoted, and with good reason—Tesla stock has earned investors a 370-fold return from its split-adjusted IPO price of $1.133. But the bigger Tesla has gotten, the harder it has been to generate returns. The company hasn’t grown profits since 2022, and now trades at roughly 200 times expected earnings over the next 12 months. The stock has barely budged since the end of 2024.

None of that is likely to keep investors away from SpaceX. Retail investors love Musk’s companies, and will likely be able to buy a heap of stock at the offering price of $135. We would recommend waiting for a better price, something closer to $90 a share.

From there, the stock could really take off—with far less chance of a blowup.

>>> This week's biggest % gainers/losers

This week's biggest % gainers/losers
The following are this week's top percentage gainers and losers, categorized by sectors (over $300 mln market cap and 100K average daily volume).

This week's top % gainers
  • Healthcare: GKOS (125.10 +21.04%), MYGN (4.56 +14.74%), TNDM (19.62 +14.07%), HUM (347.89 +13.91%)
  • Industrials: ARCB (154.01 +12.67%)
  • Consumer Discretionary: TMHC (71.46 +22.15%), TLYS (5.06 +13.34%), NWL (3.8 +11.62%)
  • Information Technology: MRVL (274.21 +33.76%), TWLO (226.48 +18.8%), HPE (49.37 +14.71%), AAOI (179.66 +13.41%)
  • Financials: STI (36.12 +676.77%), SQQQ (42.91 +12.68%)
  • Consumer Staples: EPC (19.99 +14.1%)
This week's top % losers
  • Healthcare: HRTX (0.43 -50.57%), FATE (2.02 -28.87%), EDIT (2.66 -23.27%)
  • Materials: AG (16.87 -19.97%)
  • Industrials: FLY (35.86 -22.87%), AMRC (28.01 -22.15%), BLDP (4.9 -22.1%), RUN (13.33 -20.31%), CMCO (12.93 -18.98%)
  • Consumer Discretionary: PETS (1.65 -23.96%), ETH (14.77 -22.83%), GRPN (16.39 -18.98%)
  • Information Technology: DDD (2.85 -20.17%), PI (122.82 -18.66%)

CNBC : Trump administration, OpenAI discussing possible government stake in the

Trump administration, OpenAI discussing possible government stake in the AI startup

  • OpenAI CEO Sam Altman and the White House are in ongoing talks about a possible government stake in the company, CNBC confirmed.
  • The AI startup could donate equity to the U.S. government to seed something like the “Public Wealth Fund” that the company outlined in its April policy proposal, according to a source familiar with the discussions.
  • The talks have been in progress for more than a year, as Altman first shared the idea with the Trump administration in 2025, the person said.

OpenAI CEO Sam Altman and the White House are in ongoing talks about a possible government stake in the artificial intelligence company, CNBC confirmed on Friday.

The discussions have been in progress for more than a year, as Altman first shared the idea with the Trump administration in 2025, according to a source familiar with the matter who asked not to be named because the details are confidential.

The talks continued this week as Altman met with a range of lawmakers and officials in Washington about regulation and the latest developments in AI.

As part of the potential agreement, OpenAI could donate equity to the U.S. government to seed something like the “Public Wealth Fund” that the company outlined in its April policy proposal, the person said.

OpenAI said the fund could “invest in diversified, long-term assets” and would enable citizens to participate in the “upside” of AI growth, possibly by receiving the fund’s returns directly, according to the proposal.

No official investment terms have been decided, and the details are still subject to change. Notus was first to report the recent talks.

President Donald Trump addressed the talks while on Air Force One with reporters on Friday.

“There are concepts where pieces could be given to the American public, where the American public essentially becomes a partner,” he said.

The president said he is meeting with AI companies “in the very short, very near future.”

Trump signed an executive order in February calling for the federal government to establish a sovereign wealth fund.

The Trump administration has already taken stakes in Intel
, International Business Machines and other quantum and critical mineral companies during the president’s second term.

Sen. Bernie Sanders, I-Vt., told CNBC that he and Altman discussed the concept of a sovereign wealth fund during their meeting on Wednesday.

OpenAI is valued at more than $850 billion by private investors, and the company is gearing up for an initial public offering as soon as this year. The company closed a record-breaking funding round in March that was co-led by MGX, which is backed by Abu Dhabi’s sovereign wealth fund.

Tech companies like OpenAI have played a central role in shaping the White House’s positions on the nascent technology.

Trump on Friday signed a directive instructing the federal national security organizations to “accelerate AI adoption to meet surging demand” and to rapidly onboard the “most advanced AI models from multiple vendors.”

The directive landed just days after Trump signed an executive order asking AI companies to voluntarily provide the government access to their models for up to 30 days before their release. The order is thin on specific details, but executives from leading AI companies, including Altman, voiced their support on social media.

“The U.S. should lead on AI by continuing to develop the very best models, making sure they’re safe, and getting cyber tools into the hands of trusted defenders,” Altman wrote in a post on X. “The new EO gets the balance right.”

>>> Closing Market Summary: Tech weakness, rising yields ends S&P 500 win streak

Closing Market Summary: Tech weakness, rising yields ends S&P 500 win streak at nine weeks
The stock market faced a considerable retreat today, with losses across the S&P 500 (-2.6%), Nasdaq Composite (-4.2%), and DJIA (-1.4%), resulting in lower weekly finishes for each index. For the S&P 500, this week's lower finish ends an impressive win streak at nine weeks.

The major averages faced a combination of pressures today as tech stocks extended yesterday's slide, while the Employment Situation report for May (172,000; Briefing.com consensus 96,000) beat headline expectations by a wide margin, placing upward pressure on Treasury yields amid rising expectations for a rate hike. The CME FedWatch Tool now assigns roughly a 71% probability to a rate hike at the December FOMC meeting, up from around 50% yesterday.

Growth-oriented pockets of the market generally lagged as a result, which compounded with yesterday's selloff across semiconductor stocks. The PHLX Semiconductor Index finished 10.3% lower, weighing heavily on the information technology sector (-5.3%).

Weakness was broad across the semiconductor group, with Broadcom (AVGO 385.74, -33.17, -7.92%) extending its post-earnings skid, memory names such as Micron (MU 864.01, -131.99, -13.25%) facing double-digit retreats, and other large chipmakers, including Intel (INTC 99.17, -12.61, -11.28%) and NVIDIA (NVDA 205.11, -13.55, -6.20%), moving sharply lower.

Software stocks also lagged, with Oracle (ORCL 213.41, -22.93, -9.70%) a notable decliner ahead of its earnings report next week. The iShares GS Software ETF finished 4.2% lower.

The consumer discretionary (-2.4%) and communication services (-1.7%) sectors also lagged as their mega-cap components, including Tesla (TSLA 391.00, -27.45, -6.56%) and Meta Platforms (META 593.00, -34.57, -5.51%) faced sharp retreats of their own.

The Vanguard Mega Cap Growth ETF finished 3.7% lower, contributing to the underperformance of the market-weighted S&P 500 (-2.6%) compared to the S&P 500 Equal Weighted Index (-1.5%).

On the earnings front, lululemon athletica (LULU 114.23, -10.69, -8.56%) was a notable laggard in the consumer discretionary sector after cutting its full-year outlook.

More defensive-oriented pockets of the market did garner some rotational interest today, but it was nowhere near enough support to keep the major averages from a lower finish. The consumer staples sector (+1.6%) led the way, while the utilities (+0.8%) and health care (+0.7%) sectors also posted gains.

Elsewhere, the real estate sector (+0.7%) notched a similar gain, while the financials sector (+0.1%) finished slightly higher.

Outside of the S&P 500, the Russell 2000 (-3.5%) underperformed amid the spike in Treasury yields.
Overall, today's selloff reflected the combination of an ongoing unwind across semiconductor stocks and a sharp repricing of Fed expectations following the stronger-than-expected employment report. Rising Treasury yields amplified pressure on growth-oriented areas of the market, while the limited rotation into defensive sectors was not nearly enough to offset the broad weakness across technology and mega-cap stocks.

U.S. Treasuries finished the week with sharp losses in most tenors, sending the 2-yr yield to a fresh closing high for the year while yields in the belly finished at two-week highs. The 2-year note yield settled up 11 basis points to 4.16% (+4 basis points this week) and the 10-year note yield settled up six basis points to 4.54% (-2 basis points this week).
  • Russell 2000: +14.2% YTD
  • S&P Mid Cap 400: +11.8% YTD
  • Nasdaq Composite: +10.6% YTD
  • S&P 500: +7.8% YTD
  • DJIA: +5.8% YTD

Reviewing today's data:
  • May Nonfarm Payrolls 172K (Briefing.com consensus 96K); Prior was revised to 179K from 115KMay Nonfarm Private Payrolls 120K , (Briefing.com consensus 89K); Prior was revised to 177K from 123K, May Unemployment Rate 4.3% (Briefing.com consensus 4.3%); Prior 4.3%, May Average Hourly Earnings 0.3% (Briefing.com consensus 0.3%); Prior 0.2%, May Average Workweek 34.3 (Briefing.com consensus 34.3); Prior 34.3
    • The key takeaway from the report is that it is manna for headline writers but still lacks some important sustenance to suggest it is a marker of an economy running on a full stomach. To wit: real average hourly earnings on a year-over-year basis are down 0.4%; there were job losses in the retail trade (-1,100), information (-2,000), and financial (-22,000) industries; and the percentage of unemployed workers for 27 weeks or more increased to 27.5% from 25.3%, which we will assume speaks to the difficulty of finding a new job with comparable compensation to the prior one.
  • Consumer credit increased by $20.7 billion in April (Briefing.com consensus: $17.5 billion) following a downwardly revised $22.3 billion increase (from $24.9 billion) in March.
    • The key takeaway from the report is that revolving credit growth outpaced nonrevolving credit growth in April, suggesting households may be using short-term borrowing to offset pressure from slowing real income growth and depleted savings. If this trend persists, it could support spending in the near term but raise concerns about household balance-sheet stress later.

>>> Zealand Pharma: New data from Phase 2 ZUPREME-1 trial further supports poten

Zealand Pharma: New data from Phase 2 ZUPREME-1 trial further supports potential of petrelintide to redefine the weight management experience
  • Co announces the presentation of additional data from its Phase 2 ZUPREME-1 trial, evaluating investigational petrelintide, at the 2026 Scientific Sessions of the American Diabetes Association® (ADA).
  • Results from the 42-week, Phase 2 trial show that participants who received once-weekly subcutaneous injections of petrelintide, an amylin analog, achieved clinically meaningful reductions in body weight compared to placebo.
  • Treatment with petrelintide was associated with improvements in cardiometabolic disease risk factors and was well tolerated with rates of gastrointestinal (GI)-related adverse events (AEs) generally similar to placebo.
    • Clinically meaningful, double-digit weight loss demonstrated through week 42.
    • Placebo-like tolerability observed and low rates of treatment discontinuation due to gastrointestinal adverse events.
    • Treatment associated with improvements in cardiometabolic disease risk factors, including reductions in waist circumference, high-sensitivity C-reactive protein and triglycerides.
    • Data reinforces the potential of petrelintide to enhance treatment persistence and address current challenges of treatment durability, tolerability and acceptability.
    • Phase 3 trials for chronic weight management planned for initiation in 2H26.

>>> NOVOB : Phase 2 zenagamtide trial meets A1C and body weight endpoints in typ

Phase 2 zenagamtide trial meets A1C and body weight endpoints in type 2 diabetes
- In 262 adults with type 2 diabetes inadequately controlled on metformin, with or without an SGLT2 inhibitor, once-weekly subcutaneous zenagamtide met the primary endpoint of change in A1C across all doses versus placebo after 36 weeks and the key supportive secondary endpoint of body weight change with doses 1.5 mg and greater.
- At 40 mg, zenagamtide cut A1C by up to 1.71 percentage points from a 7.8% baseline, with up to 89.1% achieving A1C below 7% and up to 76.2% at or below 6.5%.
- Zenagamtide also reduced body weight by up to 14.6% at week 36 with the 40 mg dose. Novo Nordisk plans to initiate a phase 3 development program in H2 2026.